Insiders Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 14:12:13 10/03/2026 GMT			5-day change	1st Jan Change
247.48 ^DKK	-2.76%		+6.95%	-23.87%

01:48pm	TD Cowen downgrades Novo Nordisk to hold – sees major challenges following semaglutide patent expiry	FW
01:44pm	Novo Nordisk receives FDA warning regarding US inspection in 2025	RE

Insiders

03-09	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
03-02	Novo Nordisk A/S Announces Changes of Employee Representatives to the Board of Directors	CI
02-25	Sleep Cycle Announces Executive Appointments	CI
02-24	Novo's stumbles burnish Lilly's widening lead in weight-loss drugs	RE
02-23	Novo Nordisk's CEO says still 'incredibly optimistic' about CagriSema	RE
02-23	Novo Nordisk's CEO: We need to be aware that there is an abnormality with how the comparator drug has performed in the study	RE
02-23	Novo Nordisk's CEO: I am still incredibly optimistic about Cagrisema	RE
02-23	Novo Nordisk's CEO: We strongly believe that Cagrisema has right now the best weight efficacy than any product currently on the market	RE
02-23	Novo Nordisk's chief scientific officer: assuming that there is further weight loss potential to be had with Cagrisema	RE
02-20	Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair	RE
02-20	Novo Nordisk nominates two drug industry veterans to strengthen board	RE
02-17	Camurus Names Chief Corporate Development Officer	MT
02-17	Camurus Appoints Jane Buus Laursen as Chief Corporate Development Officer, Effective March 23, 2026	CI
02-12	Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant	RE
02-09	Novo Says It's Suing Hims to Halt Obesity Drug Copycats	MT
02-09	Hims & Hers Stops Selling Wegovy Copycat Weight-Loss Pill	MT
02-09	Global markets live: Alphabet, Meta, Eli Lilly, Uber, Ocado…
02-09	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Data-Heavy Week	MT
02-09	Wall St struggles for direction as investors await key economic data	RE
02-09	PRESS DIGEST- New York Times business news - Feb 9	RE
02-04	Novo Nordisk plunges as its 2026 outlook rattles investors
02-04	Novo Nordisk CEO: The big uptake of the Wegovy pill more than justifies the reduced price	RE
02-04	Novo Nordisk CEO: We don't see our Wegovy pill price strategy as a gamble; we think it's our responsibility to be able to give all the people in need the medications that we are making	RE
02-04	Novo Nordisk CFO: Our price point in the U.S. for Wegovy is very close to compounders' price points	RE
02-04	Novo Nordisk CFO: We are looking at a percentage decline in 2026 U.S. sales in the "teens"	RE